United Therapeutics CorporationUTHRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +19.72% | +17.22% | +11.71% | +6.76% | +7.38% |
| Gross Profit Growth | +21.39% | +16.05% | +11.60% | +4.93% | +4.06% |
| EBITDA Growth | +30.81% | -10.33% | +29.00% | +10.79% | +23.63% |
| Operating Income Growth | +37.52% | +7.44% | +13.94% | +13.23% | -0.28% |
| Net Income Growth | +38.78% | +5.09% | +11.29% | +9.58% | +20.91% |
| EPS Growth | +45.89% | +10.12% | +9.58% | +11.54% | +24.04% |
| EPS Diluted Growth | +41.97% | +7.46% | +9.57% | +12.05% | +23.75% |
| Weighted Average Shares Growth | -3.83% | -4.47% | +1.58% | -1.79% | -1.99% |
| Weighted Average Shares Diluted Growth | -2.21% | -2.21% | +1.68% | -2.27% | -1.64% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +126.41% | +22.50% | -17.44% | +49.02% | +1.47% |
| Free Cash Flow Growth | +253.47% | +14.19% | -30.79% | +16.93% | -31.91% |
| Receivables Growth | +0.14% | +4.78% | +30.48% | -12.90% | +25.38% |
| Inventory Growth | +41.23% | +37.60% | +23.96% | +20.31% | +15.96% |
| Asset Growth | +2.75% | +19.22% | +17.62% | +3.20% | +7.01% |
| Book Value per Share Growth | +11.96% | +33.49% | +23.96% | +9.99% | +12.36% |
| Debt Growth | -57.14% | -66.67% | -100.00% | -100.00% | -100.00% |
| R&D Expense Growth | -11.62% | +43.13% | -4.01% | +23.19% | +4.26% |
| SG&A Expenses Growth | +22.92% | +17.80% | +7.43% | -16.70% | +30.65% |